Imagine a painkiller that works as well as the strongest drugs but doesn't cause addiction. This team found a special ingredient in the ocean that blocks pain signals differently than traditional medicine. They are now testing it in humans to prove it is safe and effective.
Chronic pain affects billions globally and costs Europe 500 billion Euros annually. Current effective treatments, specifically opioids, cause severe addiction and harmful side effects.
A first-in-class analgesic molecule called Sea4Pain derived from marine compounds, currently undergoing First-in-Human trials.
If you are a drug development corporation dealing with the high risk of opioid addiction in patients — this project developed Sea4Pain that provides a first-in-class non-opioid alternative for chronic pain.
If you are a private clinic network dealing with the 500 billion Euro economic burden of chronic pain in Europe — this project developed a marine-derived analgesic that treats pain without known side effects.
If you are a marine biotech venture dealing with the difficulty of translating ocean compounds into assets — this project developed a platform for ion channel-based drug discovery to target the multi-billion euro pain market.
Based on available project data, specific pricing or cost per dose is not provided; the project focuses on clinical validation and licensing.
The business model relies on out-licensing the technology to pharmaceutical partners to achieve rapid entry into the multi-billion euro market.
The project aims to clinically validate the molecule through First-in-Human trials and then out-license the technology to third parties.
The project runs from 2024-03-01 to 2026-08-31, focusing on the completion of First-in-Human trials.
It serves as a first-in-class replacement for opioids, offering a novel mechanism of action that avoids addiction and habituation.
The project is led by a single Portuguese SME, Sea4Us, which maintains 100% industry control. This lean structure suggests a focused approach to rapid commercialization and licensing rather than a broad academic collaboration.
Contact SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A. in Portugal
Contact us to explore licensing opportunities for non-opioid marine analgesics.
